These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
462 related articles for article (PubMed ID: 9849484)
41. Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Gupta AA; Anderson JR; Pappo AS; Spunt SL; Dasgupta R; Indelicato DJ; Hawkins DS Cancer; 2012 Feb; 118(4):1130-7. PubMed ID: 21761400 [TBL] [Abstract][Full Text] [Related]
42. A pilot study of vincristine, ifosfamide, and doxorubicin in the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas. Walter AW; Shearer PD; Pappo AS; Greenwald CA; Rao BN; Bowman LC; Furman WL; Gajjar A; Jenkins JJ; Pratt CB Med Pediatr Oncol; 1998 Apr; 30(4):210-6. PubMed ID: 9473755 [TBL] [Abstract][Full Text] [Related]
43. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study. Koscielniak E; Jürgens H; Winkler K; Bürger D; Herbst M; Keim M; Bernhard G; Treuner J Cancer; 1992 Nov; 70(10):2557-67. PubMed ID: 1482503 [TBL] [Abstract][Full Text] [Related]
44. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. Granowetter L; Womer R; Devidas M; Krailo M; Wang C; Bernstein M; Marina N; Leavey P; Gebhardt M; Healey J; Shamberger RC; Goorin A; Miser J; Meyer J; Arndt CA; Sailer S; Marcus K; Perlman E; Dickman P; Grier HE J Clin Oncol; 2009 May; 27(15):2536-41. PubMed ID: 19349548 [TBL] [Abstract][Full Text] [Related]
48. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. Le Deley MC; Paulussen M; Lewis I; Brennan B; Ranft A; Whelan J; Le Teuff G; Michon J; Ladenstein R; Marec-Bérard P; van den Berg H; Hjorth L; Wheatley K; Judson I; Juergens H; Craft A; Oberlin O; Dirksen U J Clin Oncol; 2014 Aug; 32(23):2440-8. PubMed ID: 24982464 [TBL] [Abstract][Full Text] [Related]
49. An unresolved issue in rhabdomyosarcoma treatment: The duration of chemotherapy. Bisogno G; Hawkins DS Pediatr Blood Cancer; 2020 May; 67(5):e28174. PubMed ID: 31994316 [TBL] [Abstract][Full Text] [Related]
50. Ifosfamide and Etoposide Chemotherapy in the Treatment of Recurrent/Refractory Rhabdomyosarcoma in Adults. Sasada S; Kodaira M; Shimoi T; Shimomura A; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K Anticancer Res; 2016 May; 36(5):2429-32. PubMed ID: 27127153 [TBL] [Abstract][Full Text] [Related]
51. Mecapegfilgrastim for prophylaxis of febrile neutropenia in children and adolescents with rhabdomyosarcoma or Ewing sarcoma: a prospective, single-arm, pilot study. Zhao W; Zhou Y; Wang X; Yang P; Huang C; Ma X; Su Y; Zhang R BMC Cancer; 2024 Aug; 24(1):1013. PubMed ID: 39148050 [TBL] [Abstract][Full Text] [Related]
54. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. Kushner BH; Meyers PA; Gerald WL; Healey JH; La Quaglia MP; Boland P; Wollner N; Casper ES; Aledo A; Heller G J Clin Oncol; 1995 Nov; 13(11):2796-804. PubMed ID: 7595741 [TBL] [Abstract][Full Text] [Related]
55. Results of RS-99 protocol for childhood solid tumors. Cai JY; Tang JY; Pan C; Xu M; Xue HL; Zhou M; Dong L; Ye QD; Jiang H; Shen SH; Chen J World J Pediatr; 2010 Feb; 6(1):43-9. PubMed ID: 20143210 [TBL] [Abstract][Full Text] [Related]
56. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. Kushner BH; Meyers PA J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041 [TBL] [Abstract][Full Text] [Related]
57. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital. Marina NM; Pappo AS; Parham DM; Cain AM; Rao BN; Poquette CA; Pratt CB; Greenwald C; Meyer WH J Clin Oncol; 1999 Jan; 17(1):180-90. PubMed ID: 10458232 [TBL] [Abstract][Full Text] [Related]
58. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945 [TBL] [Abstract][Full Text] [Related]
59. Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience. Zhang J; Huang Y; Sun Y; He A; Zhou Y; Hu H; Yao Y; Shen Z BMC Cancer; 2019 Dec; 19(1):1168. PubMed ID: 31791278 [TBL] [Abstract][Full Text] [Related]
60. Embryonal rhabdomyosarcoma completely resected at diagnosis: The European paediatric Soft tissue sarcoma Study Group RMS2005 experience. Bergeron C; Jenney M; De Corti F; Gallego S; Merks H; Glosli H; Ferrari A; Ranchère-Vince D; De Salvo GL; Zanetti I; Chisholm J; Minard-Colin V; Rogers T; Bisogno G; Eur J Cancer; 2021 Mar; 146():21-29. PubMed ID: 33567392 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]